These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 19151039

  • 1. Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
    Gatti F, Nasta P, Loregian A, Puoti M, Matti A, Pagni S, de Requena DG, Prestini K, Parisi SG, Bonora S, Palù G, Carosi G.
    J Antimicrob Chemother; 2009 Mar; 63(3):575-8. PubMed ID: 19151039
    [Abstract] [Full Text] [Related]

  • 2. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
    Seminari E, De Bona A, Gentilini G, Galli L, Schira G, Gianotti N, Uberti-Foppa C, Soldarini A, Dorigatti F, Lazzarin A, Castagna A.
    J Antimicrob Chemother; 2007 Oct; 60(4):831-6. PubMed ID: 17684056
    [Abstract] [Full Text] [Related]

  • 3. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM, Ait-Khaled M, Rinaldi R, Penco G, Baril JG, Cauda R, Soriano V, Pialoux G, Wire MB, Lou Y, Givens N, Craig C, Nichols WG, Barbosa I, Yeo J, TRIAD Study Group.
    J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
    [Abstract] [Full Text] [Related]

  • 4. Comment on: Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
    Lanzafame M, Lattuada E, Corsini F.
    J Antimicrob Chemother; 2009 Jul; 64(1):215-6; author reply 216. PubMed ID: 19318364
    [No Abstract] [Full Text] [Related]

  • 5. Saquinavir exposure in HIV-infected patients with chronic viral hepatitis.
    Moltó J, Llibre JM, Ribera E, Mínguez C, del Río JS, Pedrol E, Vallecillo G, Cedeño S, Valle M, Miranda C, Negredo E, Clotet B, SQV-HEP Study Group.
    J Antimicrob Chemother; 2009 May; 63(5):992-7. PubMed ID: 19279052
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation.
    Guaraldi G, Cocchi S, Codeluppi M, Di Benedetto F, Bonora S, Motta A, Luzi K, Pecorari M, Gennari W, Masetti M, Gerunda GE, Esposito R.
    Transplant Proc; 2006 May; 38(4):1138-40. PubMed ID: 16757288
    [Abstract] [Full Text] [Related]

  • 7. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
    Luber AD, Condoluci DV, Slowinski PD, Andrews M, Olson K, Peloquin CA, Pappa KA, Pakes GE, COL104422 Study Team.
    HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
    [Abstract] [Full Text] [Related]

  • 8. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
    Ruane PJ, Luber AD, Wire MB, Lou Y, Shelton MJ, Lancaster CT, Pappa KA, COL10053 Study Team.
    Antimicrob Agents Chemother; 2007 Feb; 51(2):560-5. PubMed ID: 17088488
    [Abstract] [Full Text] [Related]

  • 9. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
    Luber AD, Brower R, Kim D, Silverman R, Peloquin CA, Frank I.
    HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
    McRae M, Clay PG, Anderson PL, Glaros AG.
    Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
    [Abstract] [Full Text] [Related]

  • 11. Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3.
    Barreiro P, Martín-Carbonero L, Núñez M, Rivas P, Morente A, Simarro N, Labarga P, González-Lahoz J, Soriano V.
    Clin Infect Dis; 2006 Apr 01; 42(7):1032-9. PubMed ID: 16511772
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of Telzir (fosamprenavir).
    Wilkins E.
    J HIV Ther; 2004 Nov 01; 9(4):87-91. PubMed ID: 15731740
    [Abstract] [Full Text] [Related]

  • 13. Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels.
    Spagnuolo V, Gentilini G, De Bona A, Galli L, Uberti-Foppa C, Soldarini A, Dorigatti F, Seminari E.
    New Microbiol; 2007 Jul 01; 30(3):279-82. PubMed ID: 17802909
    [Abstract] [Full Text] [Related]

  • 14. Fosamprenavir treatment in a highly active antiretroviral therapy schedule induces a HCV-RNA decrease and a Th1 network boost in HIV/HCV-coinfected patients.
    Perrella A, Sbreglia C, D'Antonio A, Atripaldi L, Perrella O.
    Clin Microbiol Infect; 2010 Jun 01; 16(6):676-8. PubMed ID: 19681945
    [Abstract] [Full Text] [Related]

  • 15. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
    Vispo E, Mena A, Maida I, Blanco F, Cordoba M, Labarga P, Rodriguez-Novoa S, Alvarez E, Jimenez-Nacher I, Soriano V.
    J Antimicrob Chemother; 2010 Mar 01; 65(3):543-7. PubMed ID: 20032006
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
    Cao YJ, Smith PF, Wire MB, Lou Y, Lancaster CT, Causon RC, Bigelow GE, Martinez E, Fuchs EJ, Radebaugh C, McCabe S, Hendrix CW.
    Pharmacotherapy; 2008 Jul 01; 28(7):863-74. PubMed ID: 18576901
    [Abstract] [Full Text] [Related]

  • 17. Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients.
    Seminari E, Gentilini G, Galli L, Hasson H, Danise A, Carini E, Dorigatti F, Soldarini A, Lazzarin A, Castagna A.
    J Antimicrob Chemother; 2005 Oct 01; 56(4):790-2. PubMed ID: 16143711
    [Abstract] [Full Text] [Related]

  • 18. Fosamprenavir calcium plus ritonavir for HIV infection.
    Torres HA, Arduino RC.
    Expert Rev Anti Infect Ther; 2007 Jun 01; 5(3):349-63. PubMed ID: 17547501
    [Abstract] [Full Text] [Related]

  • 19. Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
    Pérez-Elias MJ, Sánchez-Conde M, Soriano V, Mallolas J, Luque I, Rodríguez-Alcántara F, Fosamprenavir Expanded Access Program Group.
    Enferm Infecc Microbiol Clin; 2009 Jan 01; 27(1):28-32. PubMed ID: 19218000
    [Abstract] [Full Text] [Related]

  • 20. Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.
    Wire MB, Baker KL, Jones LS, Shelton MJ, Lou Y, Thomas GJ, Berrey MM.
    Antimicrob Agents Chemother; 2006 Apr 01; 50(4):1578-80. PubMed ID: 16569890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.